AlphaMark Advisors LLC Invests $1.73 Million in Edwards Lifesciences Co. (NYSE:EW)

AlphaMark Advisors LLC acquired a new position in Edwards Lifesciences Co. (NYSE:EW) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 18,730 shares of the medical research company’s stock, valued at approximately $1,730,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Allspring Global Investments Holdings LLC grew its holdings in shares of Edwards Lifesciences by 4.4% in the first quarter. Allspring Global Investments Holdings LLC now owns 330,711 shares of the medical research company’s stock valued at $31,603,000 after acquiring an additional 14,087 shares in the last quarter. Empowered Funds LLC grew its holdings in shares of Edwards Lifesciences by 151.2% in the first quarter. Empowered Funds LLC now owns 20,123 shares of the medical research company’s stock valued at $1,923,000 after acquiring an additional 12,112 shares in the last quarter. Telos Capital Management Inc. grew its holdings in shares of Edwards Lifesciences by 158.2% in the fourth quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock valued at $6,970,000 after acquiring an additional 56,000 shares in the last quarter. Cetera Advisors LLC grew its holdings in shares of Edwards Lifesciences by 175.1% in the first quarter. Cetera Advisors LLC now owns 38,090 shares of the medical research company’s stock valued at $3,640,000 after acquiring an additional 24,242 shares in the last quarter. Finally, HealthInvest Partners AB bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at approximately $1,587,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

NYSE:EW traded up $1.64 during mid-day trading on Thursday, reaching $68.14. The stock had a trading volume of 5,481,319 shares, compared to its average volume of 4,058,537. The stock has a market capitalization of $41.06 billion, a P/E ratio of 29.37, a P/E/G ratio of 2.57 and a beta of 1.11. The firm has a 50 day moving average price of $81.15 and a two-hundred day moving average price of $85.80. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The business had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same period in the previous year, the firm posted $0.66 earnings per share. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. As a group, analysts expect that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 5,625 shares of the stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $90.45, for a total transaction of $508,781.25. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares in the company, valued at $2,764,242.45. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Bernard J. Zovighian sold 8,617 shares of the stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $87.68, for a total transaction of $755,538.56. Following the completion of the sale, the chief executive officer now directly owns 68,218 shares in the company, valued at $5,981,354.24. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 5,625 shares of the stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $90.45, for a total transaction of $508,781.25. Following the sale, the chief financial officer now owns 30,561 shares of the company’s stock, valued at $2,764,242.45. The disclosure for this sale can be found here. Insiders sold a total of 29,242 shares of company stock worth $2,498,870 over the last three months. Company insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on EW. Robert W. Baird lowered Edwards Lifesciences from an “outperform” rating to a “neutral” rating and reduced their price objective for the company from $102.00 to $70.00 in a report on Thursday, July 25th. Daiwa America upgraded Edwards Lifesciences to a “strong-buy” rating in a research note on Wednesday, July 31st. Stifel Nicolaus lowered their price objective on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating on the stock in a research note on Thursday, July 25th. The Goldman Sachs Group cut their target price on shares of Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Finally, Bank of America lowered shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating and lowered their price target for the company from $105.00 to $75.00 in a research report on Thursday, July 25th. Fourteen equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $82.10.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.